|
Aug 10, 2023
|
Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights
|
|
|
Aug 03, 2023
|
Nkarta to Participate at Upcoming Investor Conference
|
|
|
Jul 05, 2023
|
Nkarta Appoints Alyssa Levin Chief Financial and Business Officer
|
|
|
Jun 27, 2023
|
Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia
|
|
|
Jun 26, 2023
|
Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program
|
|
|
Jun 10, 2023
|
Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma
|
|
|
May 11, 2023
|
Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights
|
|
|
May 11, 2023
|
Nkarta to Present NKX019 Phase 1 Dose Escalation Data at European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma
|
|
|
Apr 17, 2023
|
Nkarta Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual Meeting
|
|
|
Apr 12, 2023
|
Nkarta to Participate at Upcoming Investor Conferences
|
|
